Assessment of protein oxidation in women using raloxifene

Molecular and Cellular Biochemistry

Volumn 290, Issue 1-2, 2006, Pages 97-101

  Korucuoglu U ^a   Ciftci B ^a   Gubahar O ^a   Biri, A ^a   Nas, T ^a   Gursoy R ^a   Aricioglu A ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Carbonyl group; Oxidative stress; Raloxifene

Indexed keywords

CARBONYL DERIVATIVE; PLASMA PROTEIN; RALOXIFENE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; OXIDATIVE STRESS; POSTMENOPAUSE OSTEOPOROSIS; PROTECTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN METABOLISM; TREATMENT DURATION;

AGED; FEMALE; FREE RADICALS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OXIDATION-REDUCTION; PROTEIN CARBONYLATION; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33749166778     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9172-0     Document Type: Article

References (29)

1. Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutation Research 591: 247-263, 2005
2. Katznellenbongen BS, Katznellenbongen JA: Defining the 'S' in SERM's. Science 295: 2380-2381, 2002
3. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 346: 967-974, 2002
4. Bryant HU, Wilson PK, Adrian MD, Cole HW, Philips DL, Dodge JA, Grese TA, Sluka JP, Glasebrook AL: Selective estrogen receptor modulators: pharmacological profile in the rat uterus. J Soc Gynecol Invest 3: 152A, 1996
5. Del Rio D, Stewart AJ, Pellegrini N: A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 15: 316-328, 2005
6. Berlett BS, Stadtman ER: Protein oxidation in aging, disease and oxidative stress. J Biol Chem 272: 20313-20316, 1997
7. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. Review. Clinica Chimica Acta 329: 23-38, 2003
8. Grune T, Reinheckel T, Davies KJA: Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J Biol Chem 271: 15504-15509, 1996
9. Siems WG, Zollner H, Grune T, Esterbauer H: Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-dihydroxynonene is not the main product. J Lipid Res 38: 612-622, 1997
10. Pantke U, Volk T, Schmutzler M, Kox WJ, Site N, Grune T: Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 27: 1080-1086, 1999
11. Garibaldi S, Aragno I, Odetti P, Marinari UM: Relationships between protein carbonyls, retinol, and tocopherols level in human plasma. Biochem Molec Biol Int 34: 729-736, 1994
12. Stadtman ER, Starke-Reed PE, Oliver CN, Carney JM, Floyd RA: Protein modification in aging. EXS 62: 64-72, 1992
13. Hoppe G, Ravandi A, Herrera D, Kuksis A, Hoff HF: Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J Lipid Res 38: 1347-1360, 1997
14. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn B, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 186: 464-478, 1990
15. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G: Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause: The Journal of The North American Menopause Society 10: 142-146, 2003
16. Wassmann S, Laufs U, Stamenkovic,D et al.: Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production. Circulation 105: 2083-2091, 2002
17. Lowry OH, Roseberg NJ, Farr AL, Randell RJ: Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275, 1951
18. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxi-dants, and degenerative diseases of aging. Proc Natl Acad Sci USA 90: 7915-7922, 1993
19. Cross OE, Halliwell B, Borish ET, Pryor W, Ames BN, Saul RL, McCord JM, Harmad D: DaOis Conference: oxygen radicals and human disease. Ann Intern Med 107: 526-545, 1987
20. Yalcin A, Kanit L, Durmaz G, Sargin S, Terek CH, Tanyolac B: Altered level of apurinic/apyrimidinic endonuclease redox factor-1 (Ape/Ref-1) mRNA in the hippocampus of ovariectomized rats treated by raloxifene against kainic acid. Clinical and Experimental Pharmacology and Physiology 32: 611-614, 2005
21. Biewenga E, Cabell L, Audesirk T: Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress. Neuroscience letters 373: 179-183, 2005
22. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G: Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause: The Journal of The North American Menopause Society 10: 142-146, 2003
23. Blasbichler M, Arakil-Aghajanian A, Sinzinger H: Raloxifene does not prevent fibrinogen oxidation in vitro. Med Sci Monit 11: PI1-4, 2005
24. Gomez-Zubeldia MA, Corrales S, Arbues J, Nogales AG, Millan JC: Influence of estradiol and gestagens on oxidative stress in the rat uterus. Gynecol Oncol 86: 250-258, 2002
25. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285, 2001
26. Magnusson C, Baron JA, Correia N: Et al. Breast cancer risk following long term estrogen and estrogen-progestin replacement therapy. Int J Cancer 81: 339-344, 1999
27. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351: 1451-1467, 1998
28. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919-3924, 1993
29. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. J Am Med Assoc 281: 2189-2197, 1999